Literature DB >> 24619722

Oncological outcome of primary non-metastatic soft tissue sarcoma treated by neoadjuvant isolated limb perfusion and tumor resection.

Jens Jakob1, Per-Ulf Tunn, Andrew J Hayes, Lothar R Pilz, Kai Nowak, Peter Hohenberger.   

Abstract

BACKGROUND: Isolated limb perfusion (ILP) is an effective limb salvage strategy in patients with advanced soft tissue sarcoma (STS) where surgery alone would result in significant functional morbidity or mandate an amputation. Most previous reports of patients undergoing ILP focus on limb salvage rates rather than local and distant relapse rates. Here, we report the oncological outcome of sarcoma patients treated by ILP and surgery.
METHODS: Data were retrieved from prospective ILP databases from two ILP centers following similar ILP techniques and surgical approaches. Only patients with primary, intermediate, or high grade non-metastatic STS were included.
RESULTS: The cohort comprised 90 patients. Median follow-up was 39 months (range 3-165 months). Median tumor size was 11 cm (range 5-34). Twenty of 90 (22%) patients underwent prior debulking surgery outside the centers. Twenty-nine of 90 (32%) had postoperative irradiation. Four of 90 underwent amputation either related to local recurrence or irresectability, 4 of 90 underwent amputation for treatment-related complications. Fifteen of 83 (18%) patients had local recurrences after ILP and limb sparing surgery, 39 of 90 (43%) developed metastatic disease. Twenty-two of 90 (24%) died of disease.
CONCLUSION: Preoperative ILP and tumor resection resulted in good local control in a cohort of high-risk STS patients.
© 2014 Wiley Periodicals, Inc.

Entities:  

Keywords:  ILP; TNF; local recurrence; neoadjuvant; preoperative; soft tissue sarcoma

Mesh:

Substances:

Year:  2014        PMID: 24619722     DOI: 10.1002/jso.23591

Source DB:  PubMed          Journal:  J Surg Oncol        ISSN: 0022-4790            Impact factor:   3.454


  6 in total

Review 1.  [Interdisciplinary treatment of soft tissue sarcoma of the extremities].

Authors:  J Jakob; T Henzler; B Kasper; A Marx; P Hohenberger
Journal:  Chirurg       Date:  2014-05       Impact factor: 0.955

Review 2.  Therapeutic options and postoperative wound complications after extremity soft tissue sarcoma resection and postoperative external beam radiotherapy.

Authors:  Mohamed H Abouarab; Iman L Salem; Magdy M Degheidy; Dominic Henn; Christoph Hirche; Ahmad Eweida; Matthias Uhl; Ulrich Kneser; Thomas Kremer
Journal:  Int Wound J       Date:  2017-12-05       Impact factor: 3.315

3.  Lower limb function and quality of life after ILP for soft-tissue sarcoma.

Authors:  Lars Erik Podleska; Nevda Kaya; Farhad Farzaliyev; Christoph Pöttgen; Sebastian Bauer; Georg Taeger
Journal:  World J Surg Oncol       Date:  2017-04-13       Impact factor: 2.754

4.  Regional chemotherapy by isolated limb perfusion prior to surgery compared with surgery and post-operative radiotherapy for primary, locally advanced extremity sarcoma: a comparison of matched cohorts.

Authors:  Jens Jakob; Henry G Smith; Michelle J Wilkinson; Tim Pencavel; Aisha B Miah; Joseph M Thomas; Per-Ulf Tunn; Lothar R Pilz; Dirk C Strauss; Peter Hohenberger; Andrew J Hayes
Journal:  Clin Sarcoma Res       Date:  2018-07-02

5.  Isolated limb perfusion with biochemotherapy and oncolytic virotherapy combines with radiotherapy and surgery to overcome treatment resistance in an animal model of extremity soft tissue sarcoma.

Authors:  Michelle J Wilkinson; Henry G Smith; Timothy D Pencavel; David C Mansfield; Joan Kyula-Currie; Aadil A Khan; Gráinne McEntee; Victoria Roulstone; Andrew J Hayes; Kevin J Harrington
Journal:  Int J Cancer       Date:  2016-05-24       Impact factor: 7.396

6.  Occurrence and prognosis of lymph node metastases in patients selected for isolated limb perfusion with soft tissue sarcoma.

Authors:  François Crettenand; David Martin; Stéphane Cherix; Nicolas Demartines; Maurice Matter
Journal:  J Cancer       Date:  2018-09-07       Impact factor: 4.207

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.